secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104105
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports Q4 2025 net loss $29.1M; ERAS-0015 shows early partial responses
-------------------------------------------------------------------------------

- Net loss per share $(0.10) for Q4 2025 vs. $(0.11) in Q4 2024; full-year net loss $124.5M ($0.44/share).
- Cash, equivalents, and marketable securities $341.8M at Dec 31, 2025; pro forma $434M after Jan 2026 $259M upsized financing.
- ERAS-0015 showed confirmed partial responses across multiple RAS-mutant tumors at 8 mg QD with favorable safety and PK.
- R&D expenses $23.2M in Q4, down from $26.1M YoY; total R&D $92.9M for FY 2025 vs $115.4M in FY 2024.
- Expanded ERAS-0015 license to worldwide rights; composition of matter patents issued for ERAS-0015 and ERAS-4001.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/0001193125-26-104105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/eras-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer